Romidepsin (depsipeptide, FK228) approved for the treatment of cutaneous and peripheral T-cell lymphoma treatment directly inhibits PI3K activity and strongly promotes apoptosis through its HDAC/PI3K dual inhibition [148]. The gene discussed is PIK3CA; the disease is peripheral T-cell lymphoma, not otherwise specified.